Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether erythropoietin is superior to placebo with
respect to left ventricular ejection fraction in patients with ST-elevation myocardial
infarction undergoing percutaneous coronary intervention.